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Heart involvement is the most critical and potentially lethal systemic manifestation in eosinophilic
granulomatosis with polyangiitis (EGPA).
We present a case of acute chest pain in a 58-year-old male with severe asthma, which regressed after
sublingual administration of nitroglycerine. At the time of hospital admission, there were non-speciﬁc
ST-changes on the ecg, coronary enzymes were increased, and the patient was concluded to have a
non-ST-elevation myocardial infarction, and treated as such.
A subacute cardiac catheterization showed no signs of signiﬁcant coronary stenosis. During the next
days, there was increasing pain and reduced strength in both feet. Paraclinical imaging and neurological
examinations could not explain the symptoms, and physiotherapy was initiated. At the time, no
connection to patient's diagnosis of severe asthma was made.
The patient was seen in the respiratory outpatient clinic for a routine check-up, three weeks after the
initial hospital admission. At this point, there was increasing pain in both legs and the patient had
difﬁculty walking and experienced increasing dyspnea. Blood eosinophils were elevated (12.7  109/L),
and an acute HRCT scan showed bilateral peribronchial inﬁltrates with ground glass opaciﬁcation and
small noduli.
A diagnosis of EGPA was established, and administration of systemic glucocorticoids was initiated. A
year and a half later, there is still reduced strength and sensory loss.
This case illustrates that it is important to consider alternative diagnoses in patients with atypical
symptoms and a low risk proﬁle.
Heart involvement is the most critical and potentially lethal systemic manifestation in eosinophilic
granulomatosis with polyangiitis (EGPA, formerly known as Churg-Strauss syndrome), which makes a
quick diagnosis and prompt initiation of correct treatment imperative.
© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
EGPA is a vasculitis of the small and medium size arteries. EGPA
is associated with severe asthma and eosinophilia in blood and
tissue [1]. The diagnostic criteria accordingly to the American
College of Rheumatology (ACR), is the presence of four or more of
these six:
1) Asthma, 2) Greater than ten percent eosinophils on the dif-
ferential leucocyte count, 3) Mononeuropathy (including multi-
plex) or polyneuropathy, 4) Migratory or transient pulmonary
opacities detected radiographically, 5) paranasal sinus abnormality,
6) Biopsy containing a vessel showing accumulation of eosinophils
in extravascular areas [2].g).
r Ltd. This is an open access articleThere are great variations in the clinical presentation of EGPA,
with cardiac involvement within about one third of the patients [3]
and the clinical presentation also varies according to ANCA status
with higher frequency of cardial involvement in patients with
ANCA negative status [4].
Here, we will discuss the importance of considering a diagnosis
of EGPA in patient with previously known asthma who develops
chest pain. Speciﬁcally, the presence of symptoms from more than
one organ system should lead the thought to a systemic disease
such as EGPA, being rare but serious.2. Case presentation
Sudden chest pain developed in a 56-year old male, ex-smoker
with 15 pack years, normal BMI, and very physically active, per-
forming triathlon and cycling 40 km per day.under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
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earlier the patient was diagnosed with asthma, with symptoms
related to exercise.
The asthma was highly unstable and difﬁcult to treat, with over
6 asthma exacerbations per year, requiring frequent courses of oral
prednisone. The anti-asthmatic treatment included high-dose
inhaled corticosteroids, long-acting beta-2-agonist, long-acting
anticholinergic, theophylline and montelukast.
Despite a daily dose of 15 mg prednisone daily for a period, the
patient continued to have many exacerbations. The exacerbations
receded after omalizumab was commenced. Prior to the admission
there was no worsening of the asthma symptoms.
The chest pain lasted for hours, and the patient described a
difﬁculty of reaching his standard max pulse during exercise the
days before. At admission, the respiration frequency was 13, heart
rate 60, blood pressure 110/70 and the saturation was 97% without
oxygen supplement. Auscultation examination was normal.
The electrocardiogram (ECG) showed sinus rhythm, heart rate of
55 and no signiﬁcant signs of infarction, but there was hammock-
like ST changes in the antero-lateral leads. There was a cardial
troponin I elevation up to 25800 ng/L and creatine kinase MB
elevation up to 96.7 mg/L, and an eosinophil count of 3.57 109/L, C-
Reactive protein (CRP) 8.
Echocardiography (ECCO) showed normal ejection fraction and
a computed axial tomography scan (CT) scan of the heart was also
normal.
It was suspected that the patient had a non ST-elevation
myocardial infarction, and after administration of sublingual
nitroglycerin, the pain regressed. Cardiac catheterization showed a
non-signiﬁcant stenosis, too small for intervention.
The subsequent day, the patient developed pain in the right
groin, at the sitewhere he had been catheterized. A hematomawith
a diameter of 5  10 cm was found on ultrasound, and interpreted
to be the cause of the pain. Later, in addition to the pain, the patient
described decreased sensibility and strength of the right foot.
Ultrasound of the right groin showed edema, no sign of pseudo
aneurism, and again, normal echocardiography.
On day ﬁve, the patient experienced that the left foot suddenly
gave way under him. A neurologic exam showed decreased sensi-
bility laterally on the left leg, and hewas unable to walk on toes and
heels. Because of the pain and decreased sensibility and strength, a
CT of the abdomen and a Magnetic resonance scan (MRI) of the
columna was performed. The CT scan showed no sign of retroper-
itoneal bleeding and the MRI scan showed slight protrusion of the
discus on level L4/L5, otherwise normal. Electromyography was
normal, and the assessment by the neurologist was that the
symptoms was of non-organic origin (functional).
The patient was then referred for physiotherapy and he was
released from the hospital on aspirin, brilique and simvastatin.
On day twenty-two, the patient came for a planned routine
check-up at the outpatient clinic at the department of respiratory
medicine. At this point, bilateral loss of strength was pronounced
and he was mobilized on crutches, and experienced progressive
sensory loss and dysesthesia in both legs, now with a stocking
distribution.
When examined, he was found to be short of breath, the tem-
perature was 38.4 Celsius, and there was right sided peroneal
paresis.
His eosinophil count was 12.7  109/L, antineutrophil cyto-
plasmatic antibodies (ANCA) was negative, the total white blood
cell count was 18.8  109/L and CRP 48 mg/L.
An acute high resolution CT scan (HRCT, Fig. 1) of the lungs was
performed, and showed peribronchial consolidated inﬁltrates and
areas with subpleural ground glass attenuation in the right lower
lobe (1d). Bilaterally there were small nodules. Compared to theprevious CT scan of the heart, there was now an increased size of
the heart, and pericardial effusion. ECCO showed thickening of the
myocardium, pericardial effusion (5mm), and estimated ejection
fraction of 40%. Therewas a slightly increase of troponin and creatin
kinase MB. There was no sign of arrhythmia.
The patient was admitted to a tertiary lung and cardiology
department, on suspicion of pericarditis or endocarditis, and
immunosuppressive therapy was started immediately (see below).
The diagnosis of eosinophilic granulomatosis with polyangiitis
(EGPA, formerly known as Churg-Strauss) was made on the basis of
the combination of cardial involvement, lung affection, and the
presence of polyneuropathy, and highly elevated eosinophils, on a
background of severe asthma.
3. Differential diagnosis
At the initial admission, the chest pain which regressed after
administration of nitroglycerine, and the coronary enzyme eleva-
tion, as well as the small stenosis on heart catheterization could be
explained as NSTEMI. However, the stenosis was insigniﬁcant, the
CT of the heart was normal and the patient developed neurological
symptoms shortly after admission. The hematoma in the hours
after heart catheterization could initially explain the dysesthesia,
but the increase and the loss of strength in addition, and the
dissemination to the left foot as well, were not likely to be caused
by the hematoma. The insigniﬁcant protrusion of discs seen on the
MRI could not explain the neurological symptoms, and especially
combined with the cardial involvement. Since no biopsy could
verify vasculitis, and no paraclinical examination could explain the
symptoms, it was considered that they could be of non-organic
origin. A contact to the asthma specialist who followed the pa-
tient or a MRI scan of the heart might have given the diagnosis
earlier.
The frequent treatment with prednisone could have masked
eventual previous neurological symptoms and maybe even chest
pain.
The treatment with omalizumab could have caused the angina
and the later thrombosis, as this is reported as side effects [5]. But it
seems unlikely that omalizumab alone could have caused both the
pericardial effusion, the high eosinophil count, and the neurological
symptoms.
4. Treatment
High dose methylprednisone was initiated in a dose of 1 g three
times a day for the ﬁrst three days. On day two, 800 mg of cyclo-
phosphamide was added. After the ﬁrst three days, the prednisone
dose was run down to 50 mg per day and further reduced over the
next days. The treatment with immunosuppressant was main-
tained with orally methotrexate once a week for three months, this
was then converted to intravenously administered cyclophospha-
mide once a month, because of persisting peroneal paresis and
development of a deep venous thrombosis.
5. Outcome and follow-up
At the end of the high dose methylprednisone, the eosinophil
count had normalized and the dysesthesia had regressed. Likewise,
the dyspnea disappeared. Within a few days, the TnI level
normalized, EF normalized within weeks and the pericardial effu-
sion regressed.
The following weeks, the paresis of the feet improved, but the
paresis persisted in the right peroneal nerve. A year and a half later
there is still peroneal paresis, but no sign of relapse of EGPA.
Fig. 1. High Resolution Computed axial Tomography scan showed peribronchial consolidated inﬁltrates bilaterally as well as small nodules (1aec) and areas with subpleural ground
glass attenuation in the right lower lobe (1d). Compared to the previous CT scan of the heart, there was now an increased size of the heart, and pericardial effusion.
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The patient presented here has both asthma, hypereosinophilia,
polyneuropathy and migratory inﬁltrates in both lungs, and
thereby meets four out of the six diagnostic criteria listed by the
ACR (see “Introduction”). EGPA is a rare vasculitis, and develops
especially among patients with asthma and eosinophilia [6]. This
vasculitis has both pulmonary and extra pulmonary involvement,
and there exists a great span in the clinical presentation with
symptoms from the lungs and upper airways (asthma), skin, the
cardiovascular system, the peripheral nervous system, the kidneys,
the gastrointestinal tract and the musculoskeletal system [4,6].
Cardial involvement in EGPA is serious and frequent. The most
frequent described ﬁndings are pericardial effusion and clinical
signs of heart failure [3]. ECG changes with ST abnormalities and
arrhythmias, MRI with sign of endocarditis and cardiomyopathy,
and signs of valve dysfunction and elevated troponins is also
described [3]. In the referenced study, all patients with cardial
involvement previously had no cardial symptoms. EGPA was asso-
ciated with high eosinophil count at the time of diagnosis, as was
the case presented here.
Cardial symptoms as the presenting symptom of EGPA are
described in similar cases [7e9], with manifestations such as
pericardial effusion [7e9] elevated troponins [8] and reduced left
ventricular function and ECG changes with new Q-waves [9].
Only one case was similar to ours, regarding presenting symp-
toms of angina, with no severe risk factors of heart disease, on a
background of late-onset asthma, and with concomitant develop-
ment of polyneuropathy during admission. However, fever and
transient visual disturbances was described prior to admission [10].
Only a minority of EGPA patients are positive for ANCA (14 and
28% [3,4]). Two studies have suggested that ANCA status among
EGPA patients is associated with different organ involvement.ANCA negative status was associated with cardial involvement, as it
was the case with the patient presented here. ANCA positive status
was more frequent among patients with involvement of the pe-
ripheral nerve system, kidney and symptoms from ear, nose and
throat [4,6].
The prognosis of EGPA can be assessed with the ﬁve factor score
system (FFS), where the presence of each of the following is given 1
point: 1) Cardiac involvement 2) Gastrointestinal involvement 3)
Renal insufﬁciency 4) Proteinuria 5) Central Nervous system
involvement [6]. Patients with a FSS from 0 usually achieves
remission on systemic glucocorticoid treatment, and when the
symptoms are under control, a reduction is recommended. With a
FFS 1 the typical treatment is a combination of systemic gluco-
corticoids and cyclophosphamide, either once a month or daily. The
duration remains controversial. The patient presented was given a
combination of systemic glucocorticoids and cyclophosphamide.
The subgroup of EGPA patients with negative ANCA status and
with cardiomyopathy had the poorest prognosis [4] and the prog-
nosis was also worst for patients with endocarditis [3]. This em-
phasizes the importance of avoiding delay in the diagnostic process
and initiation of treatment.7. Conclusion
In conclusion, this case emphasizes the importance of consid-
ering other causes of chest pain in a patient with a low risk proﬁle
and an atypical presentation. In particular, the development of
neurological symptoms simultaneously with cardial symptoms on
a background of severe asthma should prompt a suspicion of EGPA.
 Chest pain and TnI elevations in a patient without risk factors for
ischemic heart disease should lead to considerations regarding
alternative diagnoses.
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of extrapulmonary organ manifestations, including symptoms
of vasculitis and neuritis, should lead to a suspicion of EGPA.
 Fast and correct diagnosis and initiation of treatment is impor-
tant to prevent permanent injury, and may prevent lethal
outcomes
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